Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
Five-year overall survival curves of renal cell carcinoma patients... | Download Scientific Diagram
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry | Future Oncology
Comprehensive review of chromophobe renal cell carcinoma - ScienceDirect
Overall survival rates of 95 patients with metastatic renal cell... | Download Scientific Diagram
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine
Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
Frontiers | Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
Cancers | Free Full-Text | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
JCM | Free Full-Text | Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
xmlinkhub
Individualized therapy for metastatic renal cell carcinoma
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma | NEJM
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | NEJM
ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology
Kaplan–Meier curves depicting overall survival (OS; a, b) and... | Download Scientific Diagram
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program | Journal for ImmunoTherapy of Cancer
Five-year overall survival curves of renal cell carcinoma patients... | Download Scientific Diagram
Cancers | Free Full-Text | Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | Journal for ImmunoTherapy of Cancer | Full Text
Determinants of renal cell carcinoma invasion and metastatic competence | Nature Communications
